SCHEMBL6010178

SCHEMBL6010178

OC(c1ccc2noc(-c3cccc(Cl)c3)c2c1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 1/20 0.48
ADAM17 P78536 1/20 0.44
IP6K1 Q92551 6/20 0.40
IP6K3 Q96PC2 5/20 0.40
IP6K2 Q9UHH9 5/20 0.40
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
MAPT P10636 2/20 0.39
GFER P55789 1/20 0.39
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ATP4A P20648 2/20 0.36
ATP4B P51164 2/20 0.36
GUSB P08236 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3551493 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL3561176 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL6010272 0.77 IP6K1 (0.53) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL5548740 0.76 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL5668301 0.73 MAPT (0.47) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL29080634 0.69 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL10933962 0.68 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL1757999 0.67 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3
SCHEMBL6009609 0.67 CSF1R (0.59) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL25991593 0.66 IP6K1 (0.81) ALDH1A1SMN1; SMN2HPGDIP6K1IP6K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067531-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-27 US disclosed
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN-CILAG S.A. (FR) 2003-10-23 US disclosed
EP-1322644-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024687-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives FNTA, FNTB, RCE1 ALDH1A1 645/4885SMN1; SMN2 4873/4885HPGD 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.